Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minocycline for Acute Spontaneous Intracerebral Hemorrhage
ChiCTR2600117240Phase 4Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of minocycline in intracerebral hemorrhage (ICH) (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoints: Proportion of patients with mRS score 0–3 at 90 days and Serious adverse events (SAE). Planned start Jan 2026; status: not yet recruiting.
02
Drugs
minocycline
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on ChiCTR2600117240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117240.